2B4 dysfunction in XLP1 NK cells: More than inability to control EBV infection.


Journal

Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537

Informations de publication

Date de publication:
07 2019
Historique:
received: 03 07 2018
revised: 31 10 2018
accepted: 31 10 2018
pubmed: 6 11 2018
medline: 31 3 2020
entrez: 5 11 2018
Statut: ppublish

Résumé

X-linked lymphoproliferative disease 1 (XLP1) is a monogenic disorder caused by mutations in SH2D1A, resulting in the absence/dysfunction of the signaling lymphocyte activation molecule (SLAM)-associated protein (SAP). Consequently, SLAM receptors as 2B4 (CD244) and NTB-A (SLAMF6), upon ligand engagement, exert inhibitory instead of activating function. This causes an immune dysfunction that is worsened by the selective inability of NK and T cells to kill EBV-infected B cells with dramatic clinical sequelae (e.g. fulminant mononucleosis, hyperinflammation, lymphoma). Here we outline recent findings on the interplay between inhibitory 2B4 and the various activating receptors in NK cells. 2B4 engagement selectively blocks ITAM-dependent activating receptors as NCR and CD16, while it does not affect NKG2D and DNAM-1. Furthermore, inhibitory 2B4 participates to NK cell education, as highlighted by the existence in XLP1 patients of a large subset of fully functional NK cells that lack self-HLA specific inhibitory receptors and exert autoreactivity against mature dendritic cells.

Identifiants

pubmed: 30391652
pii: S1521-6616(18)30422-4
doi: 10.1016/j.clim.2018.10.022
pii:
doi:

Substances chimiques

CD244 protein, human 0
Signaling Lymphocytic Activation Molecule Family 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

31-36

Informations de copyright

Copyright © 2018 Elsevier Inc. All rights reserved.

Auteurs

Daniela Pende (D)

IRCCS Ospedale Policlinico San Martino, Dipartimento delle Terapie Oncologiche Integrate, Genoa, Italy. Electronic address: daniela.pende@hsanmartino.it.

Raffaella Meazza (R)

IRCCS Ospedale Policlinico San Martino, Dipartimento delle Terapie Oncologiche Integrate, Genoa, Italy.

Stefania Marcenaro (S)

IRCCS Istituto Giannina Gaslini, Dipartimento dei Laboratori di Ricerca, Genoa, Italy.

Maurizio Aricò (M)

A.O. Ospedali Riuniti Villa Sofia - Cervello, Palermo, Italy.

Cristina Bottino (C)

IRCCS Istituto Giannina Gaslini, Dipartimento dei Laboratori di Ricerca, Genoa, Italy; Dipartimento di Medicina Sperimentale, Università degli Studi di Genova, Genoa, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH